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Background
Darunavir/Ritonavir (DRV/r) dosed 600/100 mg bid has
shown good efficacy and tolerability in treatment-experi-
enced patients in clinical trials (POWER, TITAN). To
assess whether these results can be transferred to clini-
cal practice and a more diverse patient population this
prospective non-interventional Janssen-sponsored cohort
study was established.
Methods
Between August 2007 and March 2009, 340 HIV-1
infected antiretroviral-experienced patients from 62 Ger-
man centers enrolled in this non-interventional cohort.
All patients received DRV/r 600/100 mg bid as part of
their HAART. Virological and immunological response
was monitored every 3 months. Patients were followed
for up to 48 weeks.
Results
296/340 (87%) patients were male with a mean age of 47
years (SD 9.9); median time since HIV diagnosis was 12
years. At baseline, mean viral load (VL) was 4.7 log10
copies/mL (SD 5.44) with a mean CD4 count of 392
cells/mm3 (SD 251); 213 (63%) patients started therapy
with CD4 < 200 cells/mm3. Patients had been pretreated
with NRTIs (94%), PIs (88%), NNRTIs (63%), FI (11%),
INI (5%) and/or CCR5 (3%). No data is available for 17
patients. At baseline, only 138 patients received DRV/r
in combination with 2 NRTIs; the majority (202/340) of
patients received DRV/r in different combinations based
on the individual pretreatment situation. Of note, 116
patients received a combination containing DRV/r, RAL
+ other antiretrovirals. ETR and DRV/r plus other
ARVs were used in 23 patients. 51 patients received an
NRTI-sparing regimen. At the time of this analysis, 32
patients had discontinued prematurely and 251/340
patients had reached week 48. VL and CD4 measure-
ments at week 48 are available for 186 patients, 80.6 %
patients achieved a VL < 50 copies/ml (VL < 400
copies/ml: 94.6 %), mean CD4 count in these patients
(n=185) increased from 402 at baseline to 476 cells/
mm3 (SD: 262; p <0.001). 10 patients (2.9%) discontin-
ued DRV/r due to adverse events. Virological failure
(VL >50 copies/mL at 2 visits) was documented in 10
patients (2.9%). 3 patients were genotyped; primary PI
mutations were detected in all 3 patients, DRV-RAMs in
none of them.
Conclusions
Overall, Darunavir/r, dosed at 600/100 mg bid in combi-
nation with other antiretrovirals, showed good efficacy
and safety in treatment-experienced patients in clinical
practice.
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